Company: NIVFW
Filing Date: 2025-06-03
Form Type: 424B3
Source: 0001213900-25-050825
Chunk: 125

Company: NewGenIvf Group Ltd
Filing Date: 2025-06-03
Form: 424B3
Chunk 125
---
 Company derives its
revenues from two sources: (1) revenue from IVF treatment, and (2) revenue from surrogacy and ancillary caring services.

Revenue from IVF treatment

In vitro fertilization
(“IVF”) treatment is an assisted reproductive technique where eggs and sperm are collected and fertilized in laboratory to
become embryo. Fertilized embryo is then implanted to the customer or a surrogate mother. IVF treatment involves the performance of a
series of medical treatment as well as procedures and brings benefits to clients as the service of bundles service is completed. Revenue
from IVF treatment is recognized at a point in time when different treatment and/or procedure or bundles thereof, are completed in clinic.
The full completion of the various procedures and treatments are evidenced by treatment cards and reports included within the patient
files indicating successful completion of the service.

<div align='center'>74</div>

Revenue from surrogacy and ancillary caring services

The Company provides surrogacy
and ancillary caring services solely in Kyrgyzstan. Embryo from blood parents is implanted to surrogate mother contracted by the Company
or its agents. During pregnancy period, the Company provides ancillary caring services including regular body check and provision of
vitamins, supplements and medicines to surrogate mothers. The key performance obligation is identified as a single performance obligation
where a baby is born, therefore revenue from surrogacy and ancillary caring services is recognized at a point in time when surrogate
mother gives birth. The Company collects approximately 40% of contract sum upfront, and remaining contract sum is collected in installments
across pregnancy period of surrogate mother. The amount of revenue recognized from contract liabilities to the Company’s result
of operations can be found in Note 8 below.

Revenue from egg freezing and storage facility

The Company provides access
to the facility to its customers. Upon request for the service, which is agreed verbally and followed by signed consent form from the
customer, the Company makes available access to the facility with no further substantial involvement. Revenue is recognized at a point
in time when the facility is made available to the customer at the agreed consideration by the provision of specific address within the
facility as maintained in the patient file. The receipt of consideration is assured as payment is required upfront.

Principal versus agency considerations

The Company follows the
guidance provided in ASC 606, Revenue from Contracts with Customers, for determining whether the Company is the principal or an agent
in arrangements with customers that involve another party that contributes